Omeros says clinical study shows reduced incidence of CME with OMIDRIA
Omeros Corporation announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug OMIDRIA 1% / 0.3% decreases the incidence of postoperative cystoid macular edema, a sight-threatening complication of cataract surgery. The study results were presented at the joint annual meeting of the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators. The investigator-sponsored study was conducted by Keith A. Walter, M.D., Professor of Ophthalmology at Wake Forest University School of Medicine. He conducted a retrospective analysis of 504 eyes on whom he had performed cataract surgery using OMIDRIA plus only a topical non-steroidal anti-inflammatory drug, assessing the incidence of CME. The control group consisted of a collection of single and meta-analytic studies published in the peer-reviewed literature in which steroids, with and without topical NSAIDs, were used in cataract surgery in the absence of OMIDRIA. Of the 504 eyes treated with OMIDRIA, only two developed postoperative CME, an incidence of 0.39 percent, which is 3- to 12-fold lower than the CME rates in the published peer-reviewed studies using steroids both with and without NSAIDs in the absence of OMIDRIA. A manuscript reporting details of the study is in preparation and is expected to be submitted for publication in a peer-reviewed journal.